Nanjing Legend Biotech Co.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Nanjing Legend Biotech Co.
RECRUITINGNCT07100067
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of...
Sponsor: Nanjing Legend Biotech Co.Enrolling: 354 locations
Relapsed/Refractory Multiple Myeloma(MM)
RECRUITINGPhase 1NCT07331272
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic...
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
Sponsor: Nanjing Legend Biotech Co.Enrolling: 385 locations
Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathies(IIM)